ClinicalTrials.gg
CompletedNCT07404735Updated Jul 21, 2026

A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846

A Phase 1 interventional study of CKD-846 and D091 in Benign Prostate Hypertrophy(BPH), sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.

Enrollment
46th of 57
34 · median 83
Started
2026
with 6 others
Phase 1
20 of 72
4 open now
Registered
67th of 72
by date
Lead sponsor
7 of 72
Chong Kun Dang Pharmaceutical

Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 46th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, and was the 67th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846

Read the detailed description

A randomized, open-label and parallel study to evaluate the pharmacokinetics and safety of CKD-846 in healthy male subjects

03

Conditions studied

  • Benign Prostate Hypertrophy(BPH)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy man aged between 19 to 55 at screening
  2. Weight ≥ 55kg
  3. (BMI) of 18.5 to 27.0kg/m2
  4. Those who agree to from the first Product(IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial
  5. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Those who have disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder
  2. Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and within 2 years prior to the first administration of the drug
  3. Those with eye diseases including genetic degenerative retinal diseases, including retinitis pigmentosa
  4. Those with a past history of erection lasting more than 4 hours and priapism while taking PDE5 inhibitors such as tadalafil
  5. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption
  6. Persons with a history of clinically significant to drugs or additives, including ingredients of clinical investigational drugs
  7. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  8. A person who is judged to be unsuitable as a test subject in a screening test conducted within 28 days before administration of the investigational drug
  9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test.
  10. Those who has taken over-the-counter or prescription drugs, excluding topical agents without significant systemic absorption, within a specified period of time and the administered drug is judged to have an effect on this test or may affect the safety of the subject
  11. People who need to take nitrate preparations or nitric oxide donors etc. regularly or intermittently during the clinical trial period
  12. Those who continuously smoke excessively or consume caffeine or alcohol
  13. A person who consumed food containing grapefruit within 7 days before the first administration of the investigational drug
  14. Persons who participated in another clinical trial (including bioequivalence test) and received an investigational drug within 180days prior to the date of first administration of the investigational drug
  15. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days
  16. Those who have received blood transfusion in 30 days
  17. Those who are deemed insufficient to participate in clinical study by investigators
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    A1 (Test group)

    CKD-846, Single dose

    Drug: CKD-846

  • Experimental
    A2 (Test group)

    CKD-846, Single dose

    Drug: CKD-846

  • Experimental
    A3 (Test group)

    CKD-846, Single dose

    Drug: CKD-846

  • Experimental
    R (Reference group)

    D091, Multi dose

    Drug: D091

Interventions

  • DrugCKD-846

    once administration of Investigational Product

  • DrugD091

    once administration of Investigational Product

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of D091

    Concentration of During the administration period

    Time frame: Pre-dose, Post-dose Day1~Day34 (During the administration period)

  2. Plasma Concentration of CKD-846

    Concentration of During the administration period

    Time frame: Pre-dose, Post-dose Day1~Day91 (During the administration period)

07

Study locations

1 site
  • Severance Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Jun 2026, 3 months.

Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's 3 months is close to that.

Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 11, 2026
StartActual
Feb 23, 2026
Primary completionActual
Jun 2, 2026
CompletionActual
Jun 12, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404735
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 23, 2026
Primary completion
Jun 2, 2026
Completion
Jun 12, 2026
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion